Clinical Trials
201 trialsClonal Evolution in Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
National Cancer Institute (NCI)
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
National Cancer Institute (NCI)
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
National Institutes of Health Clinical Center (CC)
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
National Cancer Institute (NCI)
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Study of Lymphoma in Asia
National Institutes of Health Clinical Center (CC)
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
National Cancer Institute (NCI)
Cause and Natural Course of Pediatric-Onset Mastocytosis
National Institutes of Health Clinical Center (CC)
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
National Institutes of Health Clinical Center (CC)
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
National Institutes of Health Clinical Center (CC)
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
National Institutes of Health Clinical Center (CC)
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
National Cancer Institute (NCI)
Bortezomib in Treating Patients With Lymphoproliferative Disorders
National Cancer Institute (NCI)
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
National Cancer Institute (NCI)
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
National Cancer Institute (NCI)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
National Cancer Institute (NCI)
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
National Cancer Institute (NCI)
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Immunotoxin in Treating Patients With Leukemia or Lymphoma
National Cancer Institute (NCI)
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
National Cancer Institute (NCI)
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)